PrintThe Burrill Report
The Burrill Report (June 9, 2014): Greenwood Discusses Pricing, JOBS Act 2.0, and the Emerging Bioeconomy (.MP3,22.43 Mb)
As the 2014 BIO International Convention kicks off in San Diego June 23, executives gathering for the largest annual industry meeting should be upbeat as they enjoy robust financial markets, clinical successes, and strong product performance. We spoke to Jim Greenwood, CEO of the Biotechnology Industry Organization, about the upcoming meeting. Greenwood discussed ongoing pricing concerns, a follow-up to the JOBS Act, and why there hasn’t been much of a follow through in Washington to the Obama administration’s National Bioeconomy Blueprint.
June 05, 2014
http://www.burrillreport.com/article-greenwood_discusses_pricing_jobs_act_2_0_and_the_bioeconomy.html
BIO INTERNATIONAL CONFERENCE
Greenwood Discusses Pricing, JOBS Act 2.0, and the Bioeconomy
Podcast: June 9, 2014[Please login to post comments]
- Life Sciences M&A; Activity Sets Annual Record with $8.3B Roche Agreement to buy Intermune, Burrill Media Reports
Press Release Read More - Fitness and Personal Health Apps Could Pose Privacy Nightmare
Senator Schumer says patients’ data could be sold to third parties without their knowledge. Read More - Intel and Fox Foundation Team to Use Smartwatches to Track Parkinson's Patients
Data from wearable devices has potential to improve monitoring and treatment. Read More - Otonomy Raises $100M in Upsized IPO
Seventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August. Read More - Payers Look to Curb Spending on Specialty Drugs
Podcast: August 18, 2014 Read More - Sanofi Licenses Rights to MannKind’s Afrezza for Up to $925M
After many years of struggling, biotech lands marketing partner for inhaled insulin. Read More - New System for Classifying Cancer Could Change the Way Drugs Are Developed
Largest cancer genetic analysis reveals tumor subtype correlated to cell type rather than tissue type. Read More - Juno Therapeutics Fills Its Coffers with Another $134M
Funding for the biotech startup in hot CAR T-cell therapy space tops $300 million. Read More - Cerner Buys Siemens Health Services for $1.3B
Deal creates scale for future innovation, moving company beyond electronic medical records. Read More - Pharmas Tap Academia for Drug Discovery
Bristol-Myers teams with Allied Minds and Astellas teams with Cancer Research UK. Read More
